Announced Fri, 24 Jul · 21:44 IST
Aurobindo Pharma signs non-exclusive voluntary license with MSD for HIV drug alimatravir
Compliance View source PDF
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
₹1532.50
prior close
₹1533.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.6+0.8+1.1——————————
Up moveDown movePending
AI summary
Aurobindo Pharma signed a non-exclusive, royalty-free voluntary licensing agreement with MSD (Merck & Co.) to manufacture and supply generic alimatravir, an HIV prevention drug. The deal covers 129 Low- and Middle-Income Countries (LMICs) that account for most new HIV diagnoses globally. The agreement is signed before Phase 3 trial completion, a first in HIV prevention. Supply is subject to regulatory approvals.
Likely market impact
Positive for Aurobindo's HIV franchise. Expands potential market to 129 LMICs. Revenue depends on regulatory approvals and Phase 3 trial outcome.